BIOREGENX, INC. Annual Report - How They Did This Year

I’m putting together a guide to help you understand how BIOREGENX, INC. performed this year. My goal is to break down their recent filings so you can decide if this company fits your investment goals.

1. What does this company do?

BIOREGENX is a health and wellness company based in Chattanooga, Tennessee. They operate through three main pillars:

• DocSun: Develops AI-powered health apps like "TruScan.Ai," which use facial scanning to track heart rate, breathing, and stress.
• Microvascular Health Solutions (MVHS): Sells the "Endocalyx Pro" supplement and the "GlycoCheck" device, which measures blood vessel health in the mouth.
• NuLife Sciences: Handles marketing and sales, distributing supplements and devices directly to customers and through health practitioners.

2. Financial performance and "The Reality Check"

As of March 2026, the company had about 969 million shares outstanding. With a market value of roughly $3.72 million, the stock trades as a "penny stock," reflecting significant investor caution regarding the company’s current profitability.

The company is a pre-profit startup that spends more than it earns. For the 2025 fiscal year, the DocSun division generated $0 in revenue. While MVHS sells GlycoCheck systems—priced between $14,900 and $32,000—and supplements, these sales do not cover operating costs. The company lost over $2.5 million this year, relying on debt and the sale of additional shares to cover a monthly cash burn of $150,000 to $200,000.

3. Major wins and challenges

• The "Dilution" Factor: The company frequently issues new shares to pay off debt and consultants. In the last year, the share count grew by over 15%, which reduces the ownership percentage of existing shareholders.
• Tech Delays: The TruScan.Ai app launch is pushed to 2027, requiring the company to continue funding research without the expected subscription income.
• Contract Hurdles: While there is a partnership to integrate their AI tech into electric vehicles, this remains a "proof of concept" and has generated $0 in fees to date.

4. Financial health

The company carries about $1.8 million in debt, including a government disaster loan and high-interest private notes that lenders can swap for discounted shares. Auditors have flagged the company as a "going concern," indicating that survival depends on raising additional capital or achieving rapid growth in supplement sales.

5. Key risks

• High Share Count: With 969 million shares, even small amounts of selling can cause significant price swings, making it mathematically difficult for the stock price to rise substantially.
• Regulatory Hurdles: The FDA closely monitors the GlycoCheck device and AI algorithms; any regulatory changes could force an immediate halt to sales.
• Unproven Revenue: Current investor interest is based on the potential of AI health tech rather than the company’s thin, current profits from supplements.

6. Future outlook

The company plans a 1-for-25 reverse stock split to combine their 969 million shares into approximately 38.7 million. The goal is to lift the share price above $1.00 to meet exchange listing requirements.

Bottom line: This is a highly speculative company. While they have interesting technology, they are in a "show me the money" phase. Expect continued share issuance and high volatility until they prove they can achieve profitability without relying on debt. Before investing, consider whether you are comfortable with the risks associated with a pre-profit startup that relies on frequent share dilution to fund operations.